Anti-SLC34A2 (Lifastuzumab) -McMMAF
Product Specifications
Target
Apoptosis, Antibody-Drug Conjugates (ADCs), Microtubule Associated, Sodium Channel
Related Pathways
Cytoskeletal Signaling, Antibody-drug Conjugate/ADC Related, Apoptosis, Membrane transporter/Ion channel
Bioactivity
Anti-SLC34A2 (Lifastuzumab) -McMMAF is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked to the protective group maleimidocaproyl, and the tubulin inhibitor MMAF. The toxic component and linker in this ADC are McMMAF. Anti-SLC34A2 (Lifastuzumab) -McMMAF can induce apoptosis and is utilized in cancer research.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740158-500 1x 500 µL
Cytokeratin 17 (E3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880525-100 1x 100 µL
CD63 (MX-49.129.5), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940977-100 1x 100 µL
TGF-beta (1D11.16.8), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040391-500 1x 500 µL
CD81 / TAPA-1 (1.3.3.22), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680043-100 1x 100 µL
P21 / WAF1 (WA-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details